FDA Approves Alhemo for Patients with Hemophilia
Routine prophylaxis to prevent or reduce bleedingFor Patients with Hemophilia A or B with Inhibitors
The FDA has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with:
- Hemophilia A with factor VIII inhibitors, or
- Hemophilia B with factor IX inhibitors.
What It Is
- Alhemo is a subcutaneous (under the skin) injection, taken daily.
- It’s designed for patients who have developed inhibitors — antibodies that block standard clotting factor treatments.
Effectiveness
- In a global phase 3 trial, Alhemo reduced annual bleeding rates by 86% compared to no prophylaxis.
- Participants included 91 adults and 42 adolescents with hemophilia A or B, with inhibitors.
Safety Info
- Most common side effects: Injection site reactions and hives.
- May cause hypersensitivity (rash, itching, abdominal pain) and increased risk of blood clots.
- Not recommended for patients with serious allergies to the drug or its ingredients.
Special FDA Designations
- Priority Review
- Orphan Drug status (for rare conditions)
Alhemo offers a new preventative option for a high-risk hemophilia population where standard clotting therapies may fail.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
FDA Approves Retevmo for RET Fusion-Positive Solid Tumors
FDA Grants Full Approval to Retevmo for RET Fusion-Positive Metastatic Solid TumorsApproval expands precision medicine option for adults and children with advanced cancers The U.S. Food and Drug Administration (FDA) has granted traditional approval to Retevmo...
FDA Warning Letters Target Online Ketamine Sellers
Seven Warning Letters Signal Increased FDA Scrutiny The U.S. Food and Drug Administration (FDA) has launched a coordinated enforcement action against websites marketing unapproved ketamine-related drug products, issuing seven Warning Letters on July 7, 2026, to online...
FDA Warns Wild Arabic Herbs Over Product Cancer Claims
FDA Warns Wild Arabic Herbs Over Cancer Claims for Herbal Product FDA issued a warning letter to Wild Arabic Herbs after reviewing the company’s website and determining that its “Edral-17t” product was marketed as an unapproved new drug. FDA cited claims that the...